Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.
- 1 March 1993
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 90 (5) , 1839-1842
- https://doi.org/10.1073/pnas.90.5.1839
Abstract
Transcription of type 1 human immunodeficiency virus (HIV-1) provirus is governed by the viral long terminal repeat (LTR). Drugs can block HIV-1 replication by inhibiting activity of its LTR. We report that topotecan, beta-lapachone, and curcumin are potent and selective inhibitors of HIV-1 LTR-directed gene expression, at concentrations that have minor effects on cells. At these concentrations, each drug inhibited p24 antigen production in cells either acutely or chronically infected with HIV-1. Their target is transcriptional function of the LTR.Keywords
This publication has 23 references indexed in Scilit:
- Inhibition of HIV Replication in Acute and Chronic Infections in Vitro by a Tat AntagonistScience, 1991
- Pharmacology ofCurcuma longaPlanta Medica, 1991
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991
- Molecular Targets for AIDS TherapyScience, 1990
- Regulatory pathways governing HIV-1 replicationPublished by Elsevier ,1989
- Activation of HIV gene expression during monocyte differentiation by induction of NF-kBNature, 1989
- Prolonged activation of jun and collagenase genes by tumour necrosis factor-αNature, 1989
- Alternative Mechanisms for Activation of Human Immunodeficiency Virus Enhancer in T CellsScience, 1988
- Two distinct enhancers with different cell specificities coexist in the regulatory region of polyomaCell, 1984
- Evaluation of the toxicity of 3-allyl-β-lapachone against Trypanosma cruzi bloodstream formsMolecular and Biochemical Parasitology, 1980